13F Holdings
中文EN

NWBO NORTHWEST BIOTHERAPEUTICS INC

Pharmaceutical Preparations · OTC · SEC CIK 1072379 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY204.8%
TTM net income YoY55.8%
TTM EPS YoY50.0%
Revenue 3-yr CAGR11.1%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-1,608.8%
Net margin-1,388.8%
FCF margin-1,557.6%
EBITDA margin-1,517.8%

Returns

ROE—
ROA-74.3%
ROIC (approx.)—
Asset turnover0.05x

Leverage & solvency

Liabilities / assets160.8%
Debt / equity—
Current ratio0.03x
Interest coverage-4.89x

Cash quality & payout

Operating cash flow / net income1.09x
Accruals ratio6.6%
Payout ratio—
Capex / revenue45.0%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$1.38M$1.38M$1.93M$1.68M$1.00M
R&D expense$28.79M$34.89M$27.73M$35.51M$20.31M
SG&A expense$32.51M$33.00M$29.71M$33.35M$33.40M
Operating income-$59.91M-$66.51M-$55.51M-$67.18M-$52.70M
Interest expense$8.70M$7.77M$5.24M$6.07M$5.01M
Pretax income-$60.70M-$83.78M———
Income tax-$537,000$0$0$0$0
Net income-$60.16M-$83.78M-$62.60M-$105.03M$179.13M
EBITDA-$57.85M-$64.76M-$53.98M-$65.93M-$52.38M
EPS (basic)-0.04-0.07-0.06-0.100.21
EPS (diluted)-0.04-0.07-0.06-0.10-0.06
Weighted avg. shares (diluted)1.46B1.24B1.12M1.02M1.01M
Balance sheet
Cash & equivalents$3.04M$2.17M$2.13M$6.96M$15.17M
Current assets$5.52M$4.06M$4.12M$9.43M$17.29M
PP&E, net$17.41M$16.20M$17.28M$13.42M$15.03M
Goodwill$626,000$626,000$626,000$626,000$626,000
Intangibles$53.19M$1.29M———
Total assets$81.29M$26.73M$27.86M$31.32M$40.16M
Current liabilities$91.70M$68.27M$45.20M$126.00M$133.77M
Long-term debt$60.04M$62.68M$40.79M$21.53M$32.40M
Total debt$60.04M$62.68M$40.79M$21.53M$32.40M
Total liabilities$128.86M$105.71M$74.92M$136.37M$164.15M
Shareholders' equity-$60.28M-$94.49M-$65.77M-$128.10M-$123.99M
Net debt$57.00M$60.50M$38.67M$14.56M$17.23M
Shares outstanding1.56B1.33B1.18B1.07B948.40M
Cash flow statement
Operating cash flow-$44.76M-$57.02M-$53.64M-$52.77M-$38.30M
Capital expenditure$1.50M$1.01M———
Free cash flow-$46.27M-$58.03M———
Investing cash flow-$1.81M-$1.01M-$3.44M-$2.90M-$6.01M
Financing cash flow$49.33M$56.78M$52.76M$41.97M$48.13M
Depreciation & amortization$2.06M$1.74M$1.52M$1.25M$324,000
Stock-based compensation$1.21M$3.46M$4.41M$12.30M$15.57M

Free plan shows the latest 5 periods; Pro shows all 29 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.